Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin.
10.5468/ogs.2017.60.6.587
- Author:
Hiroyuki YAZAWA
1
;
Tsuyoshi HIRAIWA
;
Fumihiro ITO
;
Keiya FUJIMORI
Author Information
1. Department of Obstetrics and Gynecology, Fukushima Red Cross Hospital, Fukushima, Japan. ikyoku12@fukushima-med-jrc.jp
- Publication Type:Case Report
- Keywords:
Ovarian neoplasms;
Squamous cell carcinoma;
Dose-dense therapy;
Paclitaxel;
Carboplatin
- MeSH:
Abdominal Pain;
Aged;
Carboplatin*;
Carcinoma, Squamous Cell*;
Chemotherapy, Adjuvant;
Cisplatin;
Colon;
Colostomy;
Diagnosis;
Drug Therapy, Combination;
Epithelial Cells*;
Female;
Gynecology;
Humans;
Magnetic Resonance Imaging;
Neoplasm Metastasis;
Obstetrics;
Ovarian Neoplasms;
Paclitaxel*;
Recurrence;
Ultrasonography
- From:Obstetrics & Gynecology Science
2017;60(6):587-592
- CountryRepublic of Korea
- Language:English
-
Abstract:
We describe an extremely rare case of advanced pure primary ovarian squamous cell carcinoma (SCC), treated by adjuvant chemotherapy with dose-dense paclitaxel combined with carboplatin (dd-TC) plus the combination chemotherapy with irinotecan and cisplatin (CPT-P), with long-term recurrence-free survival. A 71-year-old woman complaining of lower abdominal pain was referred to our hospital and a 7-cm-diameter solid tumor was identified. She was diagnosed with a left ovarian tumor that was highly suspicious for malignancy based on ultrasonography, magnetic resonance imaging, and contrast-enhanced computed tomography. Bilateral salpingo-oophorectomy, low-anterior colon resection, and colostomy were performed. Intra- and post-operative histopathological diagnosis revealed International Federation of Gynecology and Obstetrics stage IIIc well-differentiated pure ovarian SCC. As adjuvant chemotherapy, 2 courses of dd-TC were administered, followed by 3 courses of CPT-P; the patient then underwent 4 additional courses of dd-TC. Both regimens were effective and there has been no recurrence or metastasis thus far in the 5 years since the operation.
